BioAtla to Present Evalstotug Data at the Society for Melanoma Research International Congress

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, has announced that an abstract has been accepted for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR). The congress will be held from October 10–13, 2024, in New Orleans, LA. This highlights the company's progress in advancing innovative cancer therapies. The presentation will focus on BioAtla’s investigational therapy Evalstotug (BA3071), a potent CAB anti-CTLA-4 antibody designed to deliver high exposures, enable extended dosing, and reduce immune-mediated toxicity.

William Boyle, Ph.D., will present the abstract titled "Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity" during the Developmental Immunotherapy session on Friday, October 11, 2024, from 8:00am to 10:20am CDT. The abstract will also be published in the 2024 SMR Abstract book in electronic format, providing further exposure for the company's groundbreaking research in the field of immunotherapy.